Võrdle meetodeid
Vaata valitud meetodeid kõrvuti; erinevad read on esile tõstetud.
| Population Pharmacodynamics× | Schildi analüüs× | |
|---|---|---|
| Valdkond | Farmakoloogia | Farmakoloogia |
| Perekond | Process / pipeline | Process / pipeline |
| Tekkeaasta≠ | 1992 | 1947 |
| Looja≠ | Lewis Sheiner and Stephen Roush | Henry Schild |
| Tüüp≠ | dose-response modeling | antagonism quantification |
| Algallikas≠ | Dahlström, B., & Nyberg, L. (1993). Population pharmacokinetics and pharmacodynamics. Clinical Pharmacokinetics, 24(1), 45-57. link ↗ | Schild, H. O. (1947). pA, a new scale for the measurement of drug antagonism. Journal of Physiology, 106(3), 337-357. DOI ↗ |
| Rööpnimetused≠ | PopPD, population PD, hierarchical PD modeling | Schild plot, pA2 |
| Seotud | 3 | 3 |
| Kokkuvõte≠ | Population pharmacodynamic (PopPD) modeling integrates pharmacokinetics with individual dose-response relationships across patient populations to characterize drug efficacy and tolerability. Pioneered by Lewis Sheiner and colleagues, PopPD accounts for inter-individual variability in drug effects and enables rational dose optimization and response prediction. | Schild analysis is a quantitative method for characterizing competitive receptor antagonism developed by Henry Schild in 1947. It uses dose-response curves in the presence and absence of antagonist to estimate the antagonist affinity constant (pA2), enabling standardized comparison of antagonist potency across drugs and experimental systems. |
| ScholarGateAndmestik ↗ |
|
|